Abstract
Background: The association of 5-fluorouracil (5-FU) and leucovorin is currently the most used combination in the treatment of advanced gastrointestinal neoplasms. Doxifluridine (d-FUR) is a fluoropyrimidine derivative that is converted into 5-FU inside tumor cells, where it is selectively cytotoxic. The oral administration of dFUR has been extensively investigated in colorectal carcinoma, and has been proven to be active and well tolerated. The purpose of this study was to test the effectiveness of the oral combination with dFUR plus I-leucovorin in gastric and pancreatic cancer patients. Methods: a total of 50 cases were treated with I-leucovorin 25 mg, followed 2 h later by d-FUR 1,200 mg/m2 for 5 days; the cycles were repeated every 10 days. The regimen was given for a maximum of 36 cycles or until disease progression. Twenty-six patients had gastric cancer (all of whom were pretreated with polychemotherapy) and 24 had advanced pancreatic carcinoma. Results: Objective responses were obtained in 4 (15%; 95% CI 1-29) patients with gastric cancer, and in I (4%) with pancreatic cancer. The median response duration was 4 months. All of the responses were seen in patients previously treated with 5-FU-containing regimens. The median survival in gastric cancer patients was 7 months. Toxicity was moderate: WHO grade III and IV diarrhea was observed in 14% of the cases. Conclusions: This study indicates the efficacy of oral d-FUR plus l-leucovorin as palliative treatment in gastric cancer patients. The results in Doxifluridine pancreatic carcinoma are disappointing but are in line with the published data Chemotherapy relating to fluoropyrimidines.
| Original language | English |
|---|---|
| Pages (from-to) | 54-57 |
| Number of pages | 4 |
| Journal | Oncology |
| Volume | 53 |
| Issue number | 1 |
| Publication status | Published - Jan 1996 |
Fingerprint
Keywords
- Chemotherapy
- Doxifluridine
- Fluoropyrimidine
- Gastric cancer
- Pancreatic cancer
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Doxifluridine as palliative treatment in advanced gastric and pancreatic cancer patients. / Di Bartolomeo, Maria; Bajetta, Emilio; Somma, Luisa; Carnaghi, Carlo; Bandieri, Elena; Del Vecchio, Michele; Stampino, Corroda Gallo; Buzzoni, Roberta.
In: Oncology, Vol. 53, No. 1, 01.1996, p. 54-57.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Doxifluridine as palliative treatment in advanced gastric and pancreatic cancer patients
AU - Di Bartolomeo, Maria
AU - Bajetta, Emilio
AU - Somma, Luisa
AU - Carnaghi, Carlo
AU - Bandieri, Elena
AU - Del Vecchio, Michele
AU - Stampino, Corroda Gallo
AU - Buzzoni, Roberta
PY - 1996/1
Y1 - 1996/1
N2 - Background: The association of 5-fluorouracil (5-FU) and leucovorin is currently the most used combination in the treatment of advanced gastrointestinal neoplasms. Doxifluridine (d-FUR) is a fluoropyrimidine derivative that is converted into 5-FU inside tumor cells, where it is selectively cytotoxic. The oral administration of dFUR has been extensively investigated in colorectal carcinoma, and has been proven to be active and well tolerated. The purpose of this study was to test the effectiveness of the oral combination with dFUR plus I-leucovorin in gastric and pancreatic cancer patients. Methods: a total of 50 cases were treated with I-leucovorin 25 mg, followed 2 h later by d-FUR 1,200 mg/m2 for 5 days; the cycles were repeated every 10 days. The regimen was given for a maximum of 36 cycles or until disease progression. Twenty-six patients had gastric cancer (all of whom were pretreated with polychemotherapy) and 24 had advanced pancreatic carcinoma. Results: Objective responses were obtained in 4 (15%; 95% CI 1-29) patients with gastric cancer, and in I (4%) with pancreatic cancer. The median response duration was 4 months. All of the responses were seen in patients previously treated with 5-FU-containing regimens. The median survival in gastric cancer patients was 7 months. Toxicity was moderate: WHO grade III and IV diarrhea was observed in 14% of the cases. Conclusions: This study indicates the efficacy of oral d-FUR plus l-leucovorin as palliative treatment in gastric cancer patients. The results in Doxifluridine pancreatic carcinoma are disappointing but are in line with the published data Chemotherapy relating to fluoropyrimidines.
AB - Background: The association of 5-fluorouracil (5-FU) and leucovorin is currently the most used combination in the treatment of advanced gastrointestinal neoplasms. Doxifluridine (d-FUR) is a fluoropyrimidine derivative that is converted into 5-FU inside tumor cells, where it is selectively cytotoxic. The oral administration of dFUR has been extensively investigated in colorectal carcinoma, and has been proven to be active and well tolerated. The purpose of this study was to test the effectiveness of the oral combination with dFUR plus I-leucovorin in gastric and pancreatic cancer patients. Methods: a total of 50 cases were treated with I-leucovorin 25 mg, followed 2 h later by d-FUR 1,200 mg/m2 for 5 days; the cycles were repeated every 10 days. The regimen was given for a maximum of 36 cycles or until disease progression. Twenty-six patients had gastric cancer (all of whom were pretreated with polychemotherapy) and 24 had advanced pancreatic carcinoma. Results: Objective responses were obtained in 4 (15%; 95% CI 1-29) patients with gastric cancer, and in I (4%) with pancreatic cancer. The median response duration was 4 months. All of the responses were seen in patients previously treated with 5-FU-containing regimens. The median survival in gastric cancer patients was 7 months. Toxicity was moderate: WHO grade III and IV diarrhea was observed in 14% of the cases. Conclusions: This study indicates the efficacy of oral d-FUR plus l-leucovorin as palliative treatment in gastric cancer patients. The results in Doxifluridine pancreatic carcinoma are disappointing but are in line with the published data Chemotherapy relating to fluoropyrimidines.
KW - Chemotherapy
KW - Doxifluridine
KW - Fluoropyrimidine
KW - Gastric cancer
KW - Pancreatic cancer
UR - http://www.scopus.com/inward/record.url?scp=0030025156&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030025156&partnerID=8YFLogxK
M3 - Article
C2 - 8570132
AN - SCOPUS:0030025156
VL - 53
SP - 54
EP - 57
JO - Oncology
JF - Oncology
SN - 0030-2414
IS - 1
ER -